Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial
- 20 July 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (21), 2593-2600
- https://doi.org/10.1200/jco.2011.39.3769
Abstract
Metformin is associated with reduced breast cancer risk in observational studies in patients with diabetes, but clinical evidence for antitumor activity is unclear. The change in Ki-67 between pretreatment biopsy and post-treatment surgical specimen has prognostic value and may predict antitumor activity in breast cancer. After tumor biopsy, we randomly allocated 200 nondiabetic women with operable breast cancer to either metformin 850 mg/twice per day (n = 100) or placebo (n = 100). The primary outcome measure was the difference between arms in Ki-67 after 4 weeks adjusted for baseline values. Overall, the metformin effect on Ki-67 change relative to placebo was not statistically significant, with a mean proportional increase of 4.0% (95% CI, −5.6% to 14.4%) 4 weeks apart. However, there was a different drug effect depending on insulin resistance (homeostasis model assessment [HOMA] index > 2.8, fasting glucose [mmol/L] × insulin [mU/L]/22.5; Pinteraction = .045), with a nonsignificant mean proportional decrease in Ki-67 of 10.5% (95% CI, −26.1% to 8.4%) in women with HOMA more than 2.8 and a nonsignificant increase of 11.1% (95% CI, −0.6% to 24.2%) with HOMA less than or equal to 2.8. A different effect of metformin according to HOMA index was noted also in luminal B tumors (Pinteraction = .05). Similar trends to drug effect modifications were observed according to body mass index (P = .143), waist/hip girth-ratio (P = .058), moderate alcohol consumption (P = .005), and C-reactive protein (P = .080). Metformin before surgery did not significantly affect Ki-67 overall, but showed significantly different effects according to insulin resistance, particularly in luminal B tumors. Our findings warrant further studies of metformin in breast cancer with careful consideration to the metabolic characteristics of the study population.Keywords
This publication has 45 references indexed in Scilit:
- Insulin Breast Cancer Connection: Confirmatory Data Set the Stage for Better CareJournal of Clinical Oncology, 2011
- Metformin and Incident Breast Cancer among Diabetic Women: A Population-Based Case–Control Study in DenmarkCancer Epidemiology, Biomarkers & Prevention, 2011
- Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysisCancer Prevention Research, 2010
- Metformin: A Therapeutic Opportunity in Breast CancerClinical Cancer Research, 2010
- Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and DiseaseEndocrine Reviews, 2009
- Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal WomenJNCI Journal of the National Cancer Institute, 2008
- Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapyDiabetologia, 2008
- Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studiesThe Lancet, 2008
- Insulin, insulin-like growth factors, insulin resistance, and neoplasiaThe American Journal of Clinical Nutrition, 2007
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminThe New England Journal of Medicine, 2002